In the SOPHIA trial [121], which compared margetuximab with trastuzumab in the treatment of advanced breast cancer following progression after HER2-targeted therapies, margetuximab demonstrated an increase in progression-free survival by approximately 1 month in the intention-to-treat population. This evidence concerns the gene ERBB2 and breast carcinoma.